Live Markets
Tuesday, July 28, 2026·George Town, KY·29°·Partly Cloudy
Markets Open · NYSE·Newsletter·Masthead·
VOL. XII · NO. 117Established MMXIV · George Town, Grand CaymanAtlantic Edition · $4.50

The Cayman Journal

Finance · Business · Technology · Caribbean & Global Affairs
Markets · Healthcare

Oramed Pharmaceuticals Inc. (ORMP)

NCM · Biotechnology

$4.17+0.01 (+0.24%)Quote refreshed

Sources: Yahoo Finance (quote, statistics) · SEC EDGAR (filings, insider trades, 13F holders) · company filings & press wires

Market Cap
$170.7M
P/E (TTM)
1.60
EPS
$2.60
Div Yield
6.02%
52W Range
$1.98–$5.19
Beta
1.20

Company overview

Next earnings: 2026-08-14(17d)

Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions with a technology platform for the oral delivery of therapeutic proteins. It develops ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes. The company has license agreements with Oravax Medical Inc. to commercialize oral vaccines for COVID-19. Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in New York, New York.

Peers in Biotechnology

All in industry →

Recent press releases

Oramed Pharmaceuticals Inc. has not issued a press release in this window.

SEC filings

All filings →

Oramed Pharmaceuticals Inc. has not filed an SEC document in this window.

Oramed Pharmaceuticals Inc. has no reported insider trades in the last 90 days.

Institutional holders

All holders →
As of 2025-12-31 · prior 2025-09-30
1,973,057 sh● NEW
1,900,000 sh● NEW
1,340,247 sh-23.5%
259,055 sh● NEW
3,167,231 sh0.0%
612,160 sh-27.6%
196,020 sh+75.5%
85,894 sh+100.0%

People at Oramed Pharmaceuticals Inc.

All people →

Quarterly financials

Full financials →
Revenue trend
03/25
$2.0M
NI -$7.6M
06/25
$2.0M
NI $7.5M
09/25
$2.0M
NI $48.4M
RevenueNI = Net Income
EPS trend (diluted)
Latest: $1.13
Prior: $0.31
Revenue sparkline